Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for QuidelOrtho Corporation (QDEL : NSDQ)
 
 • Company Description   
QuidelOrtho is a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems. The company's brand names include Sofia(R), Solana(R), Lyra(R), Triage(R) and QuickVue(R). Its comprehensive product portfolio includes tests for a range of infectious diseases, cardiac and autoimmune biomarkers, as well as a host of products to detect COVID-19. QuidelOrtho, formerly known as Quidel Corporation, is based in SAN DIEGO.

Number of Employees: 6,600

 
 • Price / Volume Information   
Yesterday's Closing Price: $36.34 Daily Weekly Monthly
20 Day Moving Average: 1,945,365 shares
Shares Outstanding: 67.63 (millions)
Market Capitalization: $2,457.52 (millions)
Beta: 0.13
52 Week High: $49.45
52 Week Low: $23.77
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 35.04% 27.97%
12 Week -10.43% -3.23%
Year To Date -18.43% -15.23%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
9975 SUMMERS RIDGE ROAD
-
SAN DIEGO,CA 92121
USA
ph: 858-552-1100
fax: 858-453-4338
ir@quidel.com http://www.quidelortho.com
 
 • General Corporate Information   
Officers
Brian J. Blaser - Chief Executive Officer and President
Kenneth F. Buechler - Chairman
Joseph M. Busky - Chief Financial Officer
John R. Chiminski - Director
Evelyn S. Dilsaver - Director

Peer Information
QuidelOrtho Corporation (BJCT)
QuidelOrtho Corporation (CADMQ)
QuidelOrtho Corporation (APNO)
QuidelOrtho Corporation (UPDC)
QuidelOrtho Corporation (IMTIQ)
QuidelOrtho Corporation (CYGN)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 219798105
SIC: 2835
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 07/30/25
Share - Related Items
Shares Outstanding: 67.63
Most Recent Split Date: (:1)
Beta: 0.13
Market Capitalization: $2,457.52 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.13 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $2.25 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/30/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 16.13
Trailing 12 Months: 16.90
PEG Ratio: -
Price Ratios
Price/Book: 0.82
Price/Cash Flow: 1.02
Price / Sales: 0.89
EPS Growth
vs. Year Ago Period: 105.56%
vs. Previous Quarter: 17.46%
Sales Growth
vs. Year Ago Period: -2.56%
vs. Previous Quarter: -2.12%
ROE
03/31/25 - 4.71
12/31/24 - 3.78
09/30/24 - 4.24
ROA
03/31/25 - 2.21
12/31/24 - 1.80
09/30/24 - 2.17
Current Ratio
03/31/25 - 1.20
12/31/24 - 1.22
09/30/24 - 1.38
Quick Ratio
03/31/25 - 0.66
12/31/24 - 0.69
09/30/24 - 0.81
Operating Margin
03/31/25 - 5.26
12/31/24 - 4.30
09/30/24 - 5.53
Net Margin
03/31/25 - -12.07
12/31/24 - -72.84
09/30/24 - -66.25
Pre-Tax Margin
03/31/25 - -12.35
12/31/24 - -76.59
09/30/24 - -70.97
Book Value
03/31/25 - 44.43
12/31/24 - 44.38
09/30/24 - 47.38
Inventory Turnover
03/31/25 - 2.58
12/31/24 - 2.61
09/30/24 - 2.52
Debt-to-Equity
03/31/25 - 0.70
12/31/24 - 0.72
09/30/24 - 0.68
Debt-to-Capital
03/31/25 - 41.27
12/31/24 - 41.78
09/30/24 - 40.58
 

Powered by Zacks Investment Research ©